CPI-006-001 : A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Blood / Myeloma / Lymphoma,Bowel (colorectum),Breast,Female reproductive organs,Head and neck,Lung,Sarcoma,Skin,Stomach and upper gastrointestinal tract,Urinary systemB-Cell Non Hodgkin Lymphoma,Bladder,Breast,Cervix,Colon,Colorectum,Diffuse Large Cell Lymphoma,Endometrium,Follicular Lymphoma,Head and neck,Kidney,Lung,Mantle Cell Lymphoma,Non-Small Cell Lung Cancer,Ovary,Pancreas,Prostate,Rectum,Renal cell carcinoma,Sarcoma,Squamous cell carcinoma

Trial Overview Read MoreRead more

This phase I/Ib trial is comparing a new immunotherapy agent (CPI-006) alone and in combination with two other therapies (CPI-444 and pembrolizumab) in adults diagnosed with select advanced cancers.
 

This trial is treating multiple types of cancer including Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer or Non-hodgkin Lymphoma.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

Commercial Sponsor

Corvus Pharmaceuticals, Inc

Summary

This trial contains a dose escalation cohort and dose expansion cohort. Within each cohort, there are 3 treatment Arms. In Arm A, participants will receive either an escalating or selected dose of CPI-006 administered intravenously once every 21 days until they reach a maximum tolerated dose (MTD) or until disease progression. In Arm B, participants will receive either an escalating or selected dose of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression. In Arm C, participants will receive either an escalating or selected dose of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression.

Recruiting Hospitals Read MoreRead more

Monash Health, Medical Oncology
Clayton
Early Phase Research Study Coordinator
earlyphase.oncresearch@monashhealth.org
0474 769 510

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next